Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Levodopa-Induced Dyskinesia in Parkinson's Disease
NCT04912115Phase 2Suspended
- Sponsor
- PharmaTher Holdings Ltd.
- Start
- Oct 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ketamine in levodopa-induced dyskinesia (LID), sponsored by PharmaTher Holdings Ltd. Primary endpoint: Change in the Unified Dyskinesia Rating Scale total score at 8 weeks. Started Oct 2021; status: suspended.
02
Drugs
ketamine
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT04912115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04912115.